# Nucleai: AI-Powered Spatial Biomarkers for Precision Medicine
Nucleai is an AI-driven spatial biology company that analyzes tissue images to identify predictive biomarkers for precision oncology.[1][2] Founded in 2018 and headquartered in Tel Aviv, Israel with operations in Chicago, the company develops artificial intelligence solutions that transform pathology slides into actionable clinical insights.[1][2] Nucleai serves pharmaceutical companies, biopharmaceutical firms, and clinical research institutions by enabling better drug development decisions and patient treatment selection.
The company addresses a critical gap in oncology: pathology slides contain vast amounts of untapped information about tumor biology and patient immune responses, but traditional analysis is slow, inconsistent, and subjective.[2] Nucleai's platform uses computer vision and machine learning to decode cellular interactions within tissue samples, creating spatial signatures that predict which patients will respond to specific therapies.[2][5] This capability is particularly valuable as drug development increasingly targets specific tumor subtypes and patient subgroups, requiring precise patient stratification.
Nucleai was founded by Avi Veidman, who identified critical shortcomings in traditional biopsy analysis—including long wait times and inconsistencies in pathology interpretation.[2] Veidman leveraged his expertise in big data and artificial intelligence, acquired during his service with Israeli Intelligence, to create a technological solution that could automate and standardize biomarker identification in cancer pathology.[2]
The company gained early validation when Debiopharm invested in Nucleai in 2020, recognizing the potential of spatial biology to accelerate precision oncology drug development.[2] This investment marked a pivotal moment, positioning Nucleai within a network of biopharma innovators and validating its technical approach for the pharmaceutical industry.
Nucleai operates at the intersection of three powerful trends: precision medicine adoption, AI-driven drug development, and the digitization of pathology.[3][5] As pharmaceutical companies increasingly pursue targeted therapies—particularly in high-value markets like antibody-drug conjugates (ADCs), which represent a $30 billion market—the need for accurate patient biomarkers has become critical.[3]
The company's spatial biology approach addresses a fundamental limitation of traditional genomic biomarkers: they capture only genetic information, missing the critical spatial context of how cells interact within tumors and immune microenvironments.[2][5] This positions Nucleai as a bridge between raw pathology data and actionable clinical insights, influencing how the entire biopharma industry approaches patient selection and drug development.
Nucleai's partnerships with leading research institutions and biopharma companies amplify its ecosystem impact, establishing spatial biomarkers as a standard tool in clinical development workflows.[5][8] The company is effectively reshaping expectations around what pathology data can reveal.
Nucleai is well-positioned to become the standard spatial biomarker platform for precision oncology as drug development continues fragmenting into increasingly specific patient populations. The company's backing by prominent investors—including Section 32, Sanofi, and M Ventures—combined with its clinical traction, suggests strong momentum.[3]
Looking ahead, Nucleai's growth will likely be driven by three factors: expansion of its platform across additional cancer types and therapeutic modalities (bi-specifics, immunotherapies), deeper integration into clinical workflows through partnerships like GoPath, and potential regulatory approvals for companion diagnostics.[3][4] As the biopharma industry faces mounting pressure to improve clinical trial success rates and reduce development timelines, spatial AI solutions that accelerate patient stratification will become increasingly indispensable. Nucleai's early-mover advantage in connecting spatial biology directly to drug development programs positions it to define this emerging category.
Nucleai has raised $61.0M in total across 4 funding rounds.
Nucleai's investors include M Ventures (Merck), Alt Capital, Andreessen Horowitz, Banana Capital, Buckley Ventures, Cyberstarts VC, Jude Gomila Rolling Fund, LGF, MMC Ventures, Noga Yerushalmi, Northpond Ventures, Not Boring Capital.
Nucleai has raised $61.0M across 4 funding rounds. Most recently, it raised $14.0M Venture Round in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $14.0M Venture Round | M Ventures (Merck) | |
| Mar 1, 2022 | $33.0M Series B | Alt Capital, Andreessen Horowitz, Banana Capital, Buckley Ventures, Cyberstarts VC, Jude Gomila Rolling Fund, LGF, MMC Ventures, Noga Yerushalmi, Northpond Ventures, Not Boring Capital, Omega Funds, Par Equity, Sanofi Ventures, Section 32, TLV Partners, Todd and Rahul's Angel Fund, Vertex Ventures Israel, Vibe Capital, Harry Hurst, Oliver Cameron, Scott Belsky, Yevgeny Dibrov | |
| Jul 1, 2020 | $9.0M Series A | Cyberstarts VC, Noga Yerushalmi, Sanofi Ventures, Section 32, TLV Partners, Vertex Ventures Israel, Yevgeny Dibrov | |
| Mar 1, 2018 | $5.0M Seed | Cyberstarts VC, Noga Yerushalmi, Sanofi Ventures, Section 32, TLV Partners, Vertex Ventures Israel, Yevgeny Dibrov |
